ALS Therapy Development Institute
480 Arsenal Street, Suite 201
Watertown
Massachusetts
02472
United States
Tel: 617-441-7200
Fax: 617-441-7299
Website: http://www.als.net/
16 articles about ALS Therapy Development Institute
-
FIRST DRUG CANDIDATE FROM ALS THERAPY DEVELOPMENT INSTITUTE STARTS CLINICAL TRIAL
11/28/2018
Participants Now Enrolling In Phase 1 Study On AT-1501, A Potential Treatment For ALS
-
ALS Therapy Development Institute and Anida Pharma Partner to Investigate Potential Treatments for ALS
9/10/2013
-
ALS Therapy Development Institute Adds Two Board Members
5/2/2013
-
ALS Therapy Development Institute Release: FDA Approves Clinical Trial of TDI-132 (Gilenyaв) in ALS Patients
2/11/2013
-
ALS Therapy Development Institute and To-BBB technologies BV Collaborate on Potential Treatments for Motor Neuron Disease
1/8/2013
-
ALS Therapy Development Institute and Gladstone Institute Collaborate to Discover Potential ALS Treatments
12/4/2012
-
ALS Therapy Development Institute Announces Research Agreement with Biogen Idec, Inc. (Massachusetts) and UCB Pharma to Investigate the Role of CD40L in ALS
12/19/2011
-
U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS Therapy Development Institute During Gala Event this November
6/7/2011
-
ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
2/4/2011
-
ALS Therapy Development Institute and Oxford BioMedica PLC Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
1/28/2010
-
ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
5/4/2009
-
ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease
8/19/2008
-
ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
4/8/2008
-
ALS Therapy Development Institute Signs Manufacturing Agreement with ALS Therapy Development Institute for High Quality Adenoviral Production
10/17/2007
-
ALS Therapy Development Institute Completes Gene Expression Profile of Lou Gehrig's Disease in Mice Largest Target-Discovery Program Aimed at New Treatments for Fatal Disease
10/2/2007
-
ALS Therapy Development Institute Announces Resignation of CEO James Heywood and Appointment to Board
8/23/2007